Table 1.
Baseline Characteristics.
| Total Cohort (n=823) | eGFRMDRD ≥60ml/min/1.73m2 (n=615) | eGFRMDRD <60ml/min/1.73m2 (n=208) | P-value§ | |
|---|---|---|---|---|
| Demographics: | ||||
| Age (Years) | 66 ± 11 | 65 ± 11 | 71 ± 9 | < 0.0001 |
| Male Gender (%) | 60 | 64 | 48 | < 0.0001 |
| BMI (kg/m2) | 29.5 ± 6.7 | 29.7 ± 6.7 | 28.9 ± 6.6 | 0.12 |
| Co-morbidities: | ||||
| Diabetes mellitus (%) | 29 | 23 | 45 | < 0.0001 |
| Hypertension (%) | 76 | 72 | 86 | < 0.0001 |
| Hyperlipidemia (%) | 80 | 80 | 80 | 0.68 |
| Current smoker (%) | 12 | 13 | 8 | 0.05 |
| CAD (%) | 76 | 74 | 84 | 0.002 |
| Echocardiographic Data: | ||||
| LVEF (%) | 35 (25–55) | 35 (25–50) | 40 (25–55) | 0.10 |
| Laboratory Data: | ||||
| Urea (mg/dl) | 21 (16–27) | 19 (15–23) | 35 (27–44) | < 0.0001 |
| Creatinine (mg/dl) | 0.94 (0.8–1.17) | 0.87 (0.76–1.15) | 1.41 (1.22–1.81) | < 0.0001 |
| Cystatin C (mg/dl) | 1.11 (0.92–1.41) | 1.01 (0.88–1.18) | 1.69 (1.42–2.13) | < 0.0001 |
| eGFRMDRD (ml/min/1.73m2) | 77 (60–93) | 85 (72–97) | 44 (36–53) | < 0.0001 |
| eGFRCysC (ml/min/1. 73m2) | 63 (47–80) | 71 (58–84) | 37 (30–46) | < 0.0001 |
| eGFRsCr+CysC (ml/min/1. 73m2) | 70 (53–86) | 77 (66–90) | 40 (32–48) | < 0.0001 |
| BNP (pg/ml) | 300 (118–675) | 259 (106–540) | 557 (220–1108) | < 0.0001 |
| Hemoglobin (gr/dl) | 13.2 ± 1.8 | 13.5 ± 1.7 | 12.4 ± 1.8 | < 0.0001 |
| CRP (mg/dl) | 3.8 (1.6–9) | 3.2 (1.4–7.8) | 5.5 (2.6–14.1) | < 0.0001 |
| Medications: | ||||
| ACE-I or ARB (%) | 68 | 68 | 66 | 0.49 |
| Beta-blockers (%) | 67 | 67 | 66 | 0.67 |
| Diuretic (%) | 58 | 53 | 72 | < 0.0001 |
| Aspirin (%) | 62 | 62 | 63 | 0.80 |
| Statin (%) | 59 | 60 | 57 | 0.36 |
Abbreviations: BMI, Body Mass Index; CAD, Coronary Artery Disease; LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate; BNP, brain natriuretic peptide; CRP, C-Reactive Protein; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
§
P-value for difference between eGFRMDRD ≥ 60ml/min/1.73m2 and eGFRMDRD < 60ml/min/1.73m2.